CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) announced today the national launch of the new AVONEX® (Interferon beta-1a) Nurse Services program which is designed to help people with multiple sclerosis (MS) as they begin and continue treatment with AVONEX, the most prescribed treatment for relapsing forms of MS worldwide. This new program is the latest example of Biogen Idec’s commitment to the MS community, which includes offering the best support services to patients and undertaking innovative research efforts to develop new therapeutic options.
